Skip to Content

Posts tagged with "The Dark Side"

  • Business and Markets

    Inside Scientific Information?

    Here’s a question that came up in the comments the other day, after I wrote about the recent publication suggesting possible immune-response problems with the Cas9 protein used in CRISPR. That paper sent the stocks of the major companies in the area down about 10% (well, mostly, and only after people had a weekend to… Read More
  • Business and Markets

    Incyte and Flexus: The Grappling Continues

    A couple of years back, I wrote about a case of accused stolen pharma intellectual property that looked like it would be heading to court. And here we are in 2017, and it’s. . .heading to court. The wheels of the law have been grinding along this whole time in the matter of Incyte and… Read More
  • The Dark Side

    The Ugly State of the Literature These Days

    So how’s it going out there in the land of the journals that will publish any flippin’ thing you send them? Apparently pretty well. I’m not sure if we’re still in the log phase of their growth or not, but there’s no shortage of quasi-open-access titles out there, the ones that (like reputable OA journals) Read More
  • Business and Markets

    Allergan Pulls A Fast One

    Friday brought news of a drug-company maneuver that I had never heard of, and didn’t even realize was possible. First, a bit of background; the stage needs to be set properly. One of Allergan’s products is Restasis, used for dry eyes, which is an opthalmic formulation of cyclosporine. It’s a valuable part of their portfolio… Read More
  • The Dark Side

    Thoughts on Reproducibility

    Not too long ago, I was talking to someone outside the field about the “reproducibility crisis”. They’d heard that there were many published papers whose results weren’t solid, and wanted to know if I’d encountered that. I had to tell them that yep, I sure had, and that just about anyone who’s worked in any… Read More
  • Alzheimer's Disease

    Neurotrope: A Shameful PR Stunt

    There was some Alzheimer’s news the other day, but it wasn’t actually about Alzheimer’s. Not very much. It was more about hype, press releases, and a grievous lack of understanding of statistics. Via @AndyBiotech and @biotechtoreador on Twitter, I came across this release about an announcement from a small company called Neurot… Read More
  • Cardiovascular Disease

    A Clinical Trial Torpedoed By Fraud and Incompetence

    Via @AndyBiotech on Twitter, here’s a story on some very troubling developments in offshore clinical trials. That Cardiobrief article is referring to this letter in NEJM, and the subject is the NIH’s trial of spironolactone in heart failure patients. The TOPCAT trial enrolled 3445 participants  in 6 countries (1151 in the US, 326 i… Read More
  • Business and Markets

    Lose Money Now! Ask Me How!

    Some readers will remember some odd moves in small biotechs like Galena Biosciences, Cytrx, and Lion Biotechnologies, among others. It can be hard to keep track, because there’s a lot of odd behavior down in those companies (here’s another recent example with Cyclacel). Here’s a welcome update to the earlier stories, courtesy of t… Read More
  • The Dark Side

    The Predatory Beat Goes On

    I’m not the least bit surprised by this effort. The predatory junk journals will do what ever they can think of to bring in customers and cash, with no restrictions and no shame: . . .we created a profile of a fictitious scientist named Anna O. Szust and applied on her behalf to the editorial… Read More
  • Business and Markets

    Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old generic steroid to the US market. They did no new registrational studies in the clinic, in case you’re wondering. There was a drug-drug interaction study, ADME work, that sort of thing… Read More
123...